Edouard Alphandéry’s work carried out together with his team and collaborators recognized by:

Mark and Clerk

AlphaOnco’s patent portfolio ranked as the fourth largest in terms of number of patent submitted in Nanomedicine by Mark and Clerk.

AlphaOnco’s patent portfolio covers:

- the methods of treatment using various sources of magnetosomes excitation;
- magnetosome-based products;
- magnetosome production processes.

1st family protecting chains of magnetosomes for medical applications

Treatment of cancer or tumors induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternative magnetic field, int. publ. number: WO2011061259A1, first priority US61/262,260 filed on 18/11/2009, inventors: E. Alphandéry, S. Faure, I. Chebbi.

Related publications

2nd family protecting the introduction of chelating agents in the medium of magnetotactic bacteria to boost bacterial growth:

Use of at least one chelating agent introduced into the culture medium of magnetotactic bacteria in order to stimulate the growth thereof, int. publ. number: WO2012/153247, first priority FR1153938 filed on 06/05/2011, inventors: E. Alphandéry, I. Chebbi.

Related publications

13th family protecting a method to maintain the chain arrangement of magnetosomes after lyophilization using a magnetosome formulation containing a cryo-protectant

A method to enable nanoparticles stored with a specific type of assembly to maintain this type of assembly upon reconstitution, first priority EP20220020559 submitted on 15/11/2022, inventors:E. Alphandéry, I. Chebbi.

-